# EMBER-4 (NCT05514054)

> A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05514054
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Eli Lilly and Company
- Conditions: Breast Neoplasms
- Interventions: Imlunestrant; Tamoxifen; Anastrozole; Letrozole; Exemestane
- Enrollment: 8000
- Primary outcome: Invasive Disease-Free Survival (IDFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 25
- Podcasts: 22
- X threads: 8
- Bluesky threads: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=ember-4-nct05514054

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05514054", "email": "<work email>"}; the inbox owner confirms by the emailed link.